Find and Pitch Jounalists, Get Your Story Covered

Tags: ULA Vulcan rocket Cape Canaveral digiday+Agency Culture

	Profile	Recent Articles on Subject
1	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - about 2 months ago With uncertainty roiling Big Pharma, execs are placing lower-risk bets - about 2 months ago By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years - 3 months ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - 3 months ago How pharma was instrumental in President Jimmy Carter’s global health efforts - 3 months ago Big Pharma earnings hang hope on the next generation of blockbusters - 5 months ago Why pharma megamergers may become a relic of the past - 5 months ago Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half - 8 months ago As feds crack down on PBMs for drug costs, Big Pharma could lose some of the heat - 9 months ago AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets - 11 months ago Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps - about 1 year ago How Big Pharma keeps the oncology engines hot with a host of strategies - over 1 year ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 3 months ago
3	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: With a major patent cliff coming, will JPM play host to some serious deal-making? - 3 months ago STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline - about 1 year ago
4	Emily Olsen Healthcare Dive Reporter at Healthcare Dive. Loyola, Medill alum. Chicago, Illinois HealthcareNews	Aetna sues drugmakers over alleged price-fixing scheme - 3 months ago
5	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Novo and GLP-1 compounding, Paxlovid and long Covid, and more - 3 months ago STAT+: Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds - 5 months ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 5 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 5 months ago STAT+: Teva fined $503 million for disparaging a rival and using patents to thwart competition - 5 months ago STAT+: Pharmalittle: We’re reading about ballooning 340B drug sales, Catalent reassuring customers, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 7 months ago STAT+: Pharmalittle: We’re reading about PBM practices, DOJ tussling with Regeneron, and more - 8 months ago STAT+: Pharmalittle: We’re reading about AbbVie spending on doctors, a new Lilly deal, and more - 9 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 9 months ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - 12 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - about 1 year ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about a lawsuit against J&J, Express Scripts dealings, and more - about 1 year ago STAT+: European regulators tout their accomplishments against pharma’s anticompetitive practices - about 1 year ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - about 1 year ago STAT+: Pharmalittle: FDA approvals rebound, abortion pill orders rise, and more news - over 1 year ago STAT+: Pharmalittle: Drugmakers raise prices, pharmacies fear fees, McKinsey settles - over 1 year ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - over 1 year ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - over 1 year ago STAT+: Pharmalittle: Biden pharma patent proposal spurs fears; Klobuchar questions company behind price spike of lead poisoning antidote - over 1 year ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - over 1 year ago Most drugmakers have so far ignored looming FTC deadline to withdraw or amend wayward patents - over 1 year ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - over 1 year ago STAT+: Pharmalittle: CVS to overhaul how it’s paid for drugs; Biden drug-shortage plan won’t expand chemo supplies - over 1 year ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - over 1 year ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - over 1 year ago STAT+: Pharmalittle: U.S. Senate eyes more policies for regulating PBMs; Novo claims most U.S. Wegovy patients pay less than $25 a month - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - over 1 year ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - over 1 year ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - over 1 year ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - over 1 year ago
6	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Big Pharma’s new DTC play: partnering with digital health providers - 4 months ago From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 5 months ago Pharma execs react to final drug price negotiations with Medicare - 8 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 9 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 11 months ago As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene - about 1 year ago 5 Big Pharma CEOs who saw major pay bumps in 2023 - about 1 year ago
7	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	3 closely watched drugs that failed in the clinic - 4 months ago The big rebrand: Why these 4 biopharmas changed their name this year - 4 months ago Is anyone taking the world’s priciest drugs? - 7 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 10 months ago Where competition is heating up in pharma - 10 months ago Could Novo, Lilly become first trillion-dollar healthcare companies? - about 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago
8	Rebecca Pifer Healthcare Dive Reporter @healthcaredive. New York City, United States insurancedigital health	New bipartisan legislation would force insurers, PBMs to sell pharmacy businesses - 4 months ago PBMs battle bipartisan scrutiny as lawmakers eye industry reform - 8 months ago PBMs, PhRMA trade blame over drug costs in House hearing - over 1 year ago PBMs, PhRMA trade blame over drug costs in House hearing - over 1 year ago
9	Mohana Ravindranath STAT News Health tech reporter at STAT. Oakland, CA + Washington, D.C. Health techreporting	Pfizer, Eli Lilly execs push back as senators scrutinize drugmakers’ telehealth moves - 4 months ago
10	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Pharma giant GSK is quitting BIO in latest setback for the lobbying group - 5 months ago

Journalists covering pharmaceutical companies